[go: up one dir, main page]

AU2002231500B2 - Antiangiogenic compounds and an assay for inhibitors of cell invasion - Google Patents

Antiangiogenic compounds and an assay for inhibitors of cell invasion Download PDF

Info

Publication number
AU2002231500B2
AU2002231500B2 AU2002231500A AU2002231500A AU2002231500B2 AU 2002231500 B2 AU2002231500 B2 AU 2002231500B2 AU 2002231500 A AU2002231500 A AU 2002231500A AU 2002231500 A AU2002231500 A AU 2002231500A AU 2002231500 B2 AU2002231500 B2 AU 2002231500B2
Authority
AU
Australia
Prior art keywords
group
linear
branched
optionally substituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002231500A
Other languages
English (en)
Other versions
AU2002231500A1 (en
Inventor
Raymond Andersen
Shoukat Dedhar
Aly Karsan
Andrew Minchinton
Michel Roberge
Calvin Roskelley
David Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA002332138A external-priority patent/CA2332138A1/fr
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2002231500A1 publication Critical patent/AU2002231500A1/en
Application granted granted Critical
Publication of AU2002231500B2 publication Critical patent/AU2002231500B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
AU2002231500A 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion Ceased AU2002231500B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA002332138A CA2332138A1 (fr) 2001-01-25 2001-01-25 Composes antiangiogeniques et dosage d'inhibiteurs de l'invasion cellulaire
CA2,332,138 2001-01-25
US33067001P 2001-10-26 2001-10-26
US60/330,670 2001-10-26
PCT/CA2002/000097 WO2002058679A2 (fr) 2001-01-25 2002-01-25 Composes anti-angiogeniques et dosage pour inhibiteurs d'invasion cellulaire

Publications (2)

Publication Number Publication Date
AU2002231500A1 AU2002231500A1 (en) 2003-02-06
AU2002231500B2 true AU2002231500B2 (en) 2006-04-27

Family

ID=25682349

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231500A Ceased AU2002231500B2 (en) 2001-01-25 2002-01-25 Antiangiogenic compounds and an assay for inhibitors of cell invasion

Country Status (4)

Country Link
EP (1) EP1355893A2 (fr)
JP (1) JP2004520372A (fr)
AU (1) AU2002231500B2 (fr)
WO (1) WO2002058679A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266815B2 (en) 2012-03-28 2016-02-23 University Of Central Florida Research Foundation, Inc. Anti-metastatic agents predicated upon polyamine macrocyclic conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2157594A1 (fr) * 1993-03-10 1994-09-15 Leah L. Frye Derives steroidiques; compositions pharmaceutiques a base de ces derives et leur utilisation comme antibiotiques ou comme desinfectants
US5508188A (en) * 1994-01-21 1996-04-16 The Regents Of The University Of California Method of growing cells in a mammal
WO1999035283A1 (fr) * 1997-12-15 1999-07-15 Beth Israel Deaconess Medical Center Procedes et reactifs destines a moduler la motilite des cellules
AU6074599A (en) * 1998-10-13 2000-05-01 Synchem Reserach, Inc. Biomimetic chelating agents and methods
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J org Chem (1998)63(14)4838-4841,Williams et al *

Also Published As

Publication number Publication date
EP1355893A2 (fr) 2003-10-29
JP2004520372A (ja) 2004-07-08
WO2002058679A2 (fr) 2002-08-01
WO2002058679A3 (fr) 2003-05-15

Similar Documents

Publication Publication Date Title
JP6689854B2 (ja) Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤
Russell et al. Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas
DE69631141T2 (de) Biologisch aktive peptide und ihre zubereitungen und verwendungen
FI113537B (fi) Menetelmä terapeuttisesti käyttökelpoisten indolokarbatsolijohdannaisten valmistamiseksi
KR100602529B1 (ko) 감마-글루타밀 및 베타-아스파르틸을 함유하는 면역조절화합물 및 그의 제조 방법
EP1397105B1 (fr) Composees destinees a l'inhibition de l'angiogenese
HU225297B1 (en) Bis staurosporin derivatives and pharmaceutical composition containing them
KR20150027217A (ko) 항진균성 항생 암포테리신 b의 n-치환된 제2 세대 유도체, 및 이의 제조 및 응용 방법
JP7111390B2 (ja) 癌細胞の遊走及び浸潤抑制を介した癌転移抑制剤
EP0934329A1 (fr) Glycoconjugues a base de derives modifies de camptothecine (20-o-liaison)
RU2312863C2 (ru) Тоник для роста волос
US6136857A (en) Methods for treating neoplasms with betaines
DE3832362A1 (de) Neue cyclopeptolide, verfahren zu ihrer herstellung und ihre verwendung
AU2002231500B2 (en) Antiangiogenic compounds and an assay for inhibitors of cell invasion
CZ133396A3 (en) Anthracyclin derivatives
US20030004149A1 (en) Antiangiogenic compounds and an assay for inhibitors of cell invasion
AU2002231500A1 (en) Antiangiogenic compounds and an assay for inhibitors of cell invasion
CA2435633A1 (fr) Composes anti-angiogeniques et dosage pour inhibiteurs d'invasion cellulaire
RS51576B (sr) Bifenil i naftil-fenil derivati hidroksamske kiseline
CN111943947B (zh) 1H-吡咯[2,3-b]吡啶衍生物及其合成方法与应用
EP0289203B1 (fr) Composés antitumoraux et antiviraux d'origine marine
DE69711612T2 (de) Zyklisches heptapeptidderivat der kolonialen ascidians, lissoclinum sp
KR19980013601A (ko) 신생혈관유도현상 억제 활성을 갖는 계피 유래의 신남 알데하이드 유도체, 이의 제조방법 및 이를 함유하는 조성물
JP3750983B2 (ja) 骨疾患の治療剤
CN102138921B (zh) 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)